Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TPMT | P51580 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10464639 | 0.93 | ALDH1A1 (0.49) | HTTALDH1A1MAPTTDP1CYP3A4 | |
| SCHEMBL3480822 | 0.85 | ALDH1A1 (0.58) | HTTALDH1A1MAPTTDP1CYP3A4 | |
| SCHEMBL1401369 | 0.85 | ALDH1A1 (0.53) | HTTALDH1A1MAPTTDP1CYP3A4 | |
| SCHEMBL9106099 | 0.84 | HTT (0.58) | HTTALDH1A1MAPTTDP1CYP3A4 | |
| SCHEMBL13557413 | 0.84 | ALDH1A1 (0.51) | HTTALDH1A1MAPTTDP1CYP3A4 | |
| SCHEMBL2678872 | 0.84 | ALDH1A1 (0.51) | HTTALDH1A1MAPTTDP1CYP3A4 | |
| SCHEMBL6375580 | 0.82 | HTT (0.55) | HTTALDH1A1MAPTTDP1CYP3A4 | |
| Sulfuric Acid SCHEMBL28214503 | 0.81 | HTT (0.47) | HTTALDH1A1MAPTTDP1CYP3A4 | |
| SCHEMBL5952815 | 0.81 | HTT (0.50) | HTTALDH1A1MAPTTDP1CYP3A4 | |
| SCHEMBL12584732 | 0.81 | ALDH1A1 (0.49) | HTTALDH1A1MAPTTDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725465-B2 | Biaryl acetamide compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725465-B2 | Biaryl acetamide compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2017-08-08 | — | — | US | disclosed |
| EP-3039021-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2016-07-06 | — | — | EP | disclosed |
| US-20150065468-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065468-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2015-03-05 | — | — | US | disclosed |
| WO-2015031613-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2015-03-05 | — | — | WO | disclosed |
| US-8809368-B2 | Compounds affecting gap junction activity | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809368-B2 | Compounds affecting gap junction activity | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2014-08-19 | — | — | US | disclosed |
| US-20090143425-A1 | COMPOUNDS AFFECTING GAP JUNCTION ACTIVITY | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-06-04 | — | — | US | disclosed |
| US-20080269298-A1 | Benzimidazol-1-YL-thiophene compounds for the treatment of cancer | ANDREWS CLARENCE W | 2008-10-30 | — | — | US | disclosed |
| US-20080269298-A1 | Benzimidazol-1-YL-thiophene compounds for the treatment of cancer | ANDREWS CLARENCE W | 2008-10-30 | — | — | US | disclosed |
| US-20080269298-A1 | Benzimidazol-1-YL-thiophene compounds for the treatment of cancer | ANDREWS CLARENCE W | 2008-10-30 | — | — | US | disclosed |
| US-20060074119-A1 | Thiophene compounds | SMITHKLINE BEECHAM CORPORATION | 2006-04-06 | — | — | US | disclosed |
| EP-1546137-A1 | BENZIMIDAZOL-1-YL-THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | SmithKline Beecham Corporation (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004014899-A1 | THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
| US-5015769-A | Hair dyes formed by reaction of an alcohol with a phenol in the presence of a strong base for etherification followed by amination | L'OREAL (FR) | 1991-05-14 | — | — | US | disclosed |
| US-4740622-A | 3-amino-4-nitrophenols, the process for preparation thereof and their use in dyeing keratinous fibres, and new intermediate 4,5-dinitrophenols | L'OREAL (FR) | 1988-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143425-A1 | COMPOUNDS AFFECTING GAP JUNCTION ACTIVITY | GJB2, GJA1, GAP43 | HTT 2463/4885ALDH1A1 3639/4885MAPT 2537/4885 |
| US-20060074119-A1 | Thiophene compounds | TPMT, ABCB1, CYP3A5 | HTT 742/4885ALDH1A1 532/4885MAPT 1271/4885 |
| US-20150065468-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | ERBB2, ERBB3, AADAC | HTT 2708/4885ALDH1A1 1370/4885MAPT 2862/4885 |
| US-20080269298-A1 | Benzimidazol-1-YL-thiophene compounds for the treatment of cancer | ABCB1, TP53, CCNI | HTT 3470/4885ALDH1A1 159/4885MAPT 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.